Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG108

—

4fd4f66f-222e-50d6-9cfb-a90bfe96b7cc

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • WNT_BETA_CATENIN_SIGNALING+0.339
  • APICAL_JUNCTION+0.244
  • PEROXISOME+0.235
  • APICAL_SURFACE+0.232
  • HEME_METABOLISM+0.170
  • PROTEIN_SECRETION+0.161
  • BILE_ACID_METABOLISM+0.137
  • NOTCH_SIGNALING+0.137
  • ESTROGEN_RESPONSE_EARLY+0.106
  • HEDGEHOG_SIGNALING+0.104

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.465
  • E2F_TARGETS-0.448
  • G2M_CHECKPOINT-0.419
  • MYC_TARGETS_V2-0.320
  • MYC_TARGETS_V1-0.318
  • INFLAMMATORY_RESPONSE-0.292
  • MTORC1_SIGNALING-0.273
  • P53_PATHWAY-0.264
  • PANCREAS_BETA_CELLS-0.262
  • IL6_JAK_STAT3_SIGNALING-0.242

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG123
mng-umap@100
——0.852
2SRR1313106
breast-umap@18
—B0.827
3TCGA-E2-A1IL-01A-11R-A14D-07
breast-umap@18
—B0.802
4f7683b51.cca9.4079.9e34.b9a4fdd27d85
lung-landscapes@6
—cohortA10.793
5MDT-AP-0393
medullo-epn-umap@date-based
MedMedulloblastoma0.788
6BS_264RCK7G
brain-umap@2
DNET—0.785
7TCGA-BH-A0HQ-01A-11R-A034-07
breast-umap@18
—B0.782
8s0122235
melanoma-umap@29
——0.780
9TCGA-73-7498-01A-12R-2187-07
lung-landscapes@6
—cohortA20.775
10BS_55P8HPYD
brain-umap@2
pilocytic astrocytoma—0.771

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
WNT_BETA_CATENIN_SIGNALING0.339Inavolisib— uncovered
APICAL_JUNCTION0.244Inavolisib— uncovered
PEROXISOME0.235Idelalisib— uncovered
APICAL_SURFACE0.232Temsirolimus— uncovered
HEME_METABOLISM0.170Temsirolimus— uncovered
PROTEIN_SECRETION0.161Remibrutinib— uncovered
BILE_ACID_METABOLISM0.137Inavolisib— uncovered
NOTCH_SIGNALING0.137Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.106Inavolisib— uncovered
HEDGEHOG_SIGNALING0.104Inavolisib— uncovered
ADIPOGENESIS0.099Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.086Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.083Remibrutinib— uncovered
MITOTIC_SPINDLE0.070Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.066Inavolisib— uncovered
COAGULATION0.065Binimetinib— uncovered
MYOGENESIS0.044Inavolisib— uncovered
UV_RESPONSE_DN0.041Inavolisib— uncovered
ANDROGEN_RESPONSE0.038Inavolisib— uncovered
KRAS_SIGNALING_DN0.014Remibrutinib— uncovered